



Editorial

Journal of Pharmaceutical and BioTech Industry: A New Open Access Journal

Ecevit Bilgili

Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA; bilgece@njit.edu

The pharmaceutical and biotechnology industry continues to be one of the most important industry sectors for various reasons. Pharmaceutical manufacturers are essential to the global health and well-being of the public and to the success of many countries' economies. The total revenue of the worldwide pharmaceutical market was estimated to be USD 1.6 trillion in 2023 [1]. Pharmaceutical companies create millions of jobs across the globe; however, none of these economic measures are more important than the significant impact of this industry sector on people's health.

The discovery, development, manufacture, and supply of pharmaceutical products, i.e., bench to bed, is one of the most versatile, multi-faceted, and innovative human endeavors. Many science and engineering disciplines contribute to and form the basis of pharmaceutical R&D and manufacturing. Universities, research institutes, state-governmental laboratories, and industry all conduct R&D, while it is the main job of universities to prepare the highly skilled work force required for this endeavor. Regulatory agencies play a major oversight role in ensuring the safety and efficacy of drug products and they support the development of regulatory sciences in emerging areas.

When the COVID-19 pandemic hit, the whole pharmaceutical community comprising pharmaceutical companies, universities, regulatory agencies, and other agencies like the World Health Organization as well as governments/payors, collaborated to ensure the rapid development, manufacture, and supply of the COVID-19 vaccines. The COVID-19 vaccines helped to protect people from severe disease, hospitalization, and death. As a result, millions of lives have been and will be saved thanks to the COVID-19 vaccines. In my opinion, this united effort around COVID-19 vaccines, contributed to by many countries around the world in different ways and capacities, reflects "humanity at its best," and gives us all hope for the future betterment of health conditions on earth. This concerted effort also once again demonstrated the critical role played by the pharmaceutical and biotechnology industry.

This article announces the launch of an international, peer-reviewed, open access journal—*Journal of Pharmaceutical and BioTech Industry* (ISSN: 2813-9380) [2]. With the above-mentioned spirit of cooperation among all constituencies of the pharmaceutical community, *Journal of Pharmaceutical and BioTech Industry* aims to create a platform in which scientists and engineers from academia, industry, regulatory bodies, and other governmental agencies share and complement each other's discoveries and advance science, engineering, and technology with the goal of enhancing patients' well-being. All aspects of the discovery, development, delivery, and manufacturing of drugs (drug substance, drug products including biodrugs, delivery devices, diagnostic agents, etc.) will be covered. The main criteria for publication are originality, high scientific quality, and interest to the pharmaceutical and biotech industry sectors. While studies performed by a single university, laboratory, or company are expected to be the norm, collaborative studies performed by multiple constituencies, e.g., academia–industry, academia–regulator, or academia–industry–regulator are especially welcome, as are inter- or multi-disciplinary studies.

I would like you to consider the *Journal of Pharmaceutical and BioTech Industry* for publishing your pharmaceutical research and development work, which may well be exper-



Citation: Bilgili, E. *Journal of Pharmaceutical and BioTech Industry: A New Open Access Journal*. *J. Pharm. BioTech Ind.* **2024**, *1*, 18–19. <https://doi.org/10.3390/jpbi1010003>

Received: 2 September 2024

Accepted: 5 September 2024

Published: 12 September 2024



Copyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

imental, theoretical, or both. In fact, to be able to accommodate the diverse publishing needs of our community, especially those in industry and regulatory agencies, we publish short communications, opinions, technical notes, reports, and expert perspectives in addition to the regular research articles and reviews. You will find that our growing Editorial Board has a diversity of scientific expertise from various disciplines pertinent to drug discovery, development, delivery, and manufacturing. I aim to ensure a sufficiently diverse Editorial Board in terms of scientific expertise, gender, race, and geographic location.

The *Journal of Pharmaceutical and BioTech Industry* offers several benefits to authors. First, the rapid and timely publication of your research results is taken seriously because we all want our exciting findings to be shared with other scientists without any delays. Second, owing to open access, your findings will not be restricted in terms of accessibility. The Creative Commons Attribution (CC BY) license allows you the utmost flexibility to share, copy, redistribute, and adapt your materials. Some print journals impose serious limitations on authors as to how they can share, reuse, and adapt their published materials, which is quite unfavorable to the authors. Third, there is no restriction on the maximum length of the manuscripts or the number of figures and tables. In fact, we recommend that full experimental details and/or methods of study be provided in the submitted research articles.

Finally, I wish to extend a warm welcome to all current and future members of the Editorial Board. As the Founding Editor-in-Chief, I invite experts and leaders from academia, industry, and regulatory agencies to join us. Let us work together to build the *Journal of Pharmaceutical and BioTech Industry*.

Conflicts of Interest: The author declares no conflicts of interest.

References

1. Mikulic, M. Global Pharmaceutical Industry—Statistics & Facts. *Statista*. Available online: <https://www.statista.com/topics/1764/global-pharmaceutical-industry/> (accessed on 2 September 2024).
2. *Journal of Pharmaceutical and BioTech Industry* Home Page. Available online: <https://www.mdpi.com/journal/jpbi> (accessed on 2 September 2024).

Short Biography of Author



Prof. Dr. Ecevit Bilgili is a professor, master teacher, and associate chair of the Chemical and Materials Engineering department at the New Jersey Institute of Technology (NJIT), USA. His Particle Engineering and Pharmaceutical Nanotechnology Laboratory conducts research in designing formulations and processes for high-value-added products like pharmaceuticals with enhanced functionalities. Before joining NJIT, he worked at Merck and Co., Inc. as a senior principal development engineer and played an instrumental role in the formulation and process development of Janumet® and other drugs in the pipeline. Prof. Dr. Bilgili served as an elected Executive Committee Member of the Particle Technology Forum of AIChE. He also served as the Chair and Vice Chair of AIChE Area3a: Particle Production and Characterization. He authored 110+ peer-reviewed journal articles, 6 U.S. patents, several invention disclosures, and has delivered 120+ national/international conference presentations and 40+ invited talks. Prof. Dr. Bilgili currently serves as an Associate Executive Editor of *Advanced Powder Technology*, an Editorial Advisory Board member of *Pharmaceutical Research*, and an Editorial Board Member of *Pharmaceutics* and *Powders* journals. He is the recipient of numerous Excellence in Teaching Awards from NJIT and the George Klinzing Best Ph.D. Thesis in Particle Technology Award from the AIChE. Prof. Dr. Bilgili was elected to the AIChE fellowship in 2022. He is in Stanford University's list of "the top 2% of the most-cited scientists".

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.